(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 21.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Mirum Pharmaceuticals's revenue in 2026 is $569,609,000.On average, 12 Wall Street analysts forecast MIRM's revenue for 2026 to be $40,113,451,121, with the lowest MIRM revenue forecast at $37,649,809,550, and the highest MIRM revenue forecast at $42,106,927,431. On average, 12 Wall Street analysts forecast MIRM's revenue for 2027 to be $48,448,365,227, with the lowest MIRM revenue forecast at $41,549,559,016, and the highest MIRM revenue forecast at $53,900,696,733.
In 2028, MIRM is forecast to generate $61,713,001,724 in revenue, with the lowest revenue forecast at $53,451,874,902 and the highest revenue forecast at $73,177,472,400.